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Background: Lymphomas of the orbit and orbital adnexae are rare tumors, comprising only 1% of all non-Hodgkin’s
lymphoma. The majority of non-Hodgkin’s lymphomas of the orbit are extranodal marginal-zone B-cell lymphomas of
mucosa-associated lymphoid tissue type. Because of nonspecific clinical signs and symptoms, some diagnostic delay
may occur. The purpose of the study was to evaluate the diagnostic approach in orbital lymphomas and to analyze
their treatment outcome.
Methods: In the period from 2005 to 2012, from a group of 135 patients with tumors of the orbit, we identified 11
patients diagnosed with orbital lymphoma. This patient cohort was reviewed retrospectively.
Results: The patient group consisted of 11 patients (seven females, male males) with a median age of 57.7 years
(range 42 to 88 years). Orbital swelling, pain and motility impairment were the leading clinical symptoms. Diagnosis was
confirmed by surgical biopsy. Depending on the anatomic location of the tumor, a surgical biopsy was taken using a
blepharoplasty incision, a lateral orbitotomy or a navigation-guided biopsy. The predominant histology was extranodal
non-Hodgkin’s lymphoma of mucosa-associated lymphoid tissue type (82%). All patients underwent complete clinical
staging. These were clinical stage IEA in seven patients, and stages IIEA (n = 2) and IIIEA (n = 2) in four patients . Patients in
stage IEA were treated with radiation therapy alone, with radiation doses between 25 and 40 Gy, and patients with stage
IIEA received systemic chemotherapy with bendamustin/rituximab. Those two patients diagnosed with diffuse large
B-cell lymphoma and mantle cell lymphoma received systemic chemotherapy according to the R-CHOP protocol.
Conclusions: Owing to unspecific clinical symptoms, some diagnostic delay may occur in orbital lymphoma. If
unspecific orbital symptoms are present, adequate imaging studies followed by early surgical biopsy will contribute to
early diagnosis. Once diagnosis is established and staging is complete, radiation therapy is the recommended treatment
for stage IEA patients. Systemic chemotherapy is indicated in selected stage IIEA patients and in patients with stage IIIEA
disease.
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Orbital lymphomas are rare, comprising only 1% of all
non-Hodgkin’s lymphoma [1]. However, lymphomas are
the most common primary orbital tumor in adults 60 years
of age and older [2]. Margo and Mulla reported in their
study of more than 300 orbital malignancies a 55% rate of
lymphomas involving the orbit [3]. The majority of non-
Hodgkin’s lymphomas of the orbit and orbital adnexa are
extranodal marginal-zone B-cell lymphomas of mucosa-
associated lymphoid tissue (MALT)-type lymphomas [4].* Correspondence: eckardt.andre@mh-hannover.de
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reproduction in any medium, provided the orAlthough initially described in the stomach and associ-
ated with Helicobacter pylori infection, MALT lymph-
omas have subsequently been observed to arise in other
epithelial structures, including the thyroid, parotid gland,
lung and breast, as well as in the orbit [5-7].
Our study aimed at exploring the diagnostic and thera-
peutic approach as well as the clinical course of lymphomas
involving the orbit.Methods
A retrospective review of orbital tumors (n = 135) treated
at the Department of Cranio-Maxillofacial Surgery from
January 2005 to April 2012 retrieved 11 cases of non-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient and treatment characteristics of orbital
lymphomas (n = 11)
Characteristic Number of patients %
Age (years)
Median 57.7















Computed tomography 10 91
Magnetic resonance imaging 8 73
Staging procedure
Chest X-ray 5 46
Chest computed tomography 8 73
Abdominal computed tomography 7 64
Bone marrow biopsy 7 64
Surgical treatment
Surgical biopsy 10 91
Complete surgical removal 1 9
Surgical approach
Transconjunctival 3 27
Blepharoplasty incision 7 64
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orbital region. All 11 patients had been referred to our
institution from the Department of Ophthalmology for
further diagnosis of an indolent swelling in the or-
bital/periorbital region.
The initial clinical staging included a computed tom-
ography or magnetic resonance imaging scan of the or-
bital/periorbital region to localize the tumor site and
extension. Based on imaging findings, a surgical biopsy
under general anesthesia was planned; in selected pa-
tients, depending on the anatomic location, the biopsy
was taken using a computer-assisted navigation platform
(iPlan CMF 3.0; Brainlab, Feldkirchen, Germany). Histo-
logic diagnosis was initially performed on H & E-stained
paraffin sections and additional immunohistochemical
staining performed for further immunologic phenotyping.
Once diagnosis was confirmed patients were staged
according to the Ann Arbor classification. Following
complete clinical staging based on the clinical practice of
the treating physician, patients were sent to the radiation
oncologist or the oncologist for further treatment plan-
ning. Post-treatment follow-up visits were organized by
the treating physicians. For the purpose of this analysis,
the treating physicians were contacted to obtain the latest
follow-up information of all patients.
Results
Clinical and pathologic features
Eleven patients were included in this analysis. Of the 11
patients, seven were women (64%) and four were men
(36%), with a median age of 57.7 years (range, 42.5 to
88.7 years). The most common presenting signs and
symptoms were periorbital tumor mass in six patients
(55%), exophthalmos in five patients (45%), ocular pain
in four patients (36%), and eye motility and visual re-
strictions in one patient (9%). One patient (9%) was
found to have bilateral disease. The tumor was located
in the supraorbital region in six patients (55%), the
retrobulbar orbital tissue in two patients (18%), and the
infraorbital region in three patients (27%). Table 1 dis-
plays patient characteristics, including age, gender, site,
diagnostic imaging, and surgical treatment.
Orbital computed tomography and/or magnetic reson-
ance imaging scans were used in all patients to evaluate
the extent of the disease and to aid in radiation treat-
ment planning.
Initial treatment consisted of a surgical biopsy under
general anesthesia in all patients using various surgical
approaches. A blepharoplasty incision was used in seven
patients (64%), combined with navigation-assisted biopsy
for retrobulbar space location in three patients (27%). A
transconjunctival approach was used in three patients
(27%). In one patient a biopsy was taken following
hemicoronal incision and a lateral orbitotomy approach(Figure 1a to e). One patient with involvement of the
lacrimal gland received complete surgical removal as the
primary treatment (Figure 2a,b).
Histopathological examination together with immuno-
histochemical studies were performed on paraffin sections
from biopsy specimens of all 11 patients. Extranodal
MALT lymphoma was diagnosed in nine patients (82%),
and the other two patients were diagnosed with diffuse
large B-cell lymphoma and with recurrence of mantle cell
lymphoma, respectively.
Figure 1 A patient underwent hemicoronal incision and a lateral orbitotomy approach, followed by a biopsy. (a) Clinical picture of a 56-
year-old patient with a history of right orbital proptosis for 2 months with no visual impairment. (b) Axial magnetic resonance imaging scan
showing tumor lesion of the intraconal/extraconal compartment of the right orbit. As a diagnostic procedure, a surgical biopsy was performed
using a hemicoronal approach: (c) the lateral orbital rim was exposed via a hemicoronal approach; (d) following temporary osteotomy of the
lateral orbital rim, the tumor was exposed and a biopsy was taken; and (e) correct anatomic reposition of the right lateral orbital rim and fixation
using a 1.3 mm titanium plate.
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Once the diagnosis was confirmed by the pathologist,
patients were discussed within the multidisciplinary
tumor board and sent for consultation to the oncologist
and/or radiation oncologist. Additional clinical staging
was performed based on the clinical practice of the
treating physician. Staging procedures included chest ra-
diographs or thoracic computed tomography scan, as
well as abdominal computed tomography scan. In se-
lected patients a bone marrow biopsy was taken. After
complete staging evaluation, seven patients (64%)
presented in stage IEA, and four patients in stage IIEA
(n = 2) and stage IIIEA (n = 2). Patients with stage IEA
MALT lymphoma (n = 7) also received radiotherapy as
the initial treatment, with radiation given 5 days per
week using a conventional fractionation size of 180 to
250 cGy. The mean radiation dose was 3,400 cGy
(range, 2,500 to 4,000 cGy). Extraorbital recurrencewas detected in only one patient with initial stage IEA
after 24 months; this tumor was controlled with salvage
radiotherapy. Two patients with stage IIEA MALT lympho-
ma received chemotherapy with bendamustin and ritu-
ximab as initial treatment and achieved complete response
after four and six cycles of chemotherapy, respectively.
The two patients with mantle cell lymphoma (stage
IIIEA) and diffuse large B-cell lymphoma (stage IIIEA) re-
ceived chemotherapy with R-CHOP (rituximab, cyclo-
phosphamide, doxorubicin,vincristine, and prednisolone)
as initial treatment. Both patients achieved complete re-
sponse after six cycles of R-CHOP.
As of June 2012, information on the survival status was
obtained for all 11 patients, with a median follow-up of
0.9 years (range, 0.2 to 6.2 years). Ten patients (91%) are
alive with no evidence of disease. One patient with stage
IEA MALT lymphoma died 1 year after completion of
radiotherapy due to intercurrent disease.
Figure 2 A patient with involvement of the lacrimal gland
received complete surgical removal as primary treatment. (a)
Coronal computed tomography scan showing a tumor lesion in the
upper right orbit of a 77-year-old woman. (b) The tumor was
exposed using a blepharoplasty approach and completely removed
together with the lacrimal gland.
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No specific guidelines currently exist for the manage-
ment of MALT lymphomas, except for localized primary
gastric MALT lymphoma. Numerous reports confirm
the efficacy of conventional treatment strategies such as
surgery, radiotherapy or chemotherapy, alone or incombination, with no significant survival difference
[6,8,9]. Surgery as the only treatment modality should
not be administered, because there is obviously a high
likelihood of local relapse after surgery according to pre-
vious reports [10]. The difficulty of complete resection
with preservation of function in the orbit may explain
the high relapse rate.
Radiation therapy as the initial treatment has been
reported to be very effective in MALT lymphoma of the
orbit [11-28]. Radiotherapy with a dose range of 25 to
35 Gy seems to be a standard approach because it pro-
vides local control and cure for localized orbital lymph-
oma [11,13,28]. Our data support these findings that
excellent local control as well as survival can be achieved
in stage IEA MALT lymphoma of the orbit by radiother-
apy alone with a mean dose of 34 Gy. However, even
after lower radiation dose recommendations in recent
publications, there is still some controversy regarding
the optimal radiation dose for this tumor [17-19]. Only
one extraorbital relapse (one out of nine MALT lymph-
omas, 11%) with skin infiltration in the upper neck de-
veloped 2 years after primary radiotherapy with 36 Gy.
Radiation doses above 35 Gy resulted in significant late
complications such as cataract formation or keratitis
[28]. It should be noted that lens shielding has to be
added after a dose of 20 Gy [19]. Interestingly several
studies have reported a relatively high local or distant
failure rate after successful initial radiotherapy. Jenkins
and colleagues reported that 47% of their study population
of 192 patients with orbital MALT lymphoma developed
extraorbital recurrence after 5 years [29]. Hasegawa and
colleagues reported a recurrence rate of 25% out of 20 pa-
tients who were treated with radiotherapy alone for orbital
MALT lymphoma and developed a relapse in the
nonirradiated orbit or at distant sites after a median
follow-up of 71 months [14]. In view of some conflicting
reports it is difficult to draw final conclusions, but all
those sometimes contradictory results point to some vari-
ance in the biologic behavior of MALT lymphomas.
There is some evidence that combination chemother-
apy is effective in orbital lymphoma [30]. Chemotherapy
has never been systematically evaluated in orbital MALT
lymphoma because of excellent local control rates in
stage IE disease that showed excellent response after pri-
mary radiotherapy. Most often, chemotherapy was ad-
ministered after either surgery or radiotherapy or was
reserved for patients with advanced disease stages IIIEA
and IVEA. With some ongoing controversial discussion
as far as the role of chemotherapy in MALT lymphoma
is concerned, it may be concluded that the development
of novel systemic strategies particularly for stages IIIEA
and IVEA is needed [8,31]. The clinical efficacy of rituxi-
mab, a chimeric mAb directed against the B-cell-specific
antigen CD20, was first demonstrated in follicular
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tended over the last few years to other subtypes of non-
Hodgkin lymphomas with promising results, as a single
agent or in combination with chemotherapy [32]. Since
CD20 antigen is expressed on the surface of neoplastic
cells in virtually all MALT lymphomas, one can assume
that rituximab is active in this neoplastic disease.
Conconi and colleagues could demonstrate clinical activ-
ity in extranodal MALT lymphomas in a phase II study
in previously untreated and treated adult patients with a
response rate of 73% and a median response duration of
10.5 months [32]. A recent pilot study assessed the toler-
ability and activity of intralesional injection rituximab in
a small group of five patients with orbital B-cell lymph-
oma, and demonstrated complete remission in two pa-
tients and stable disease in two patients [33]. Further
clinical trials will show some potential synergistic action
between rituximab and chemotherapy and will contrib-
ute to better define the role of chemotherapy in
extranodal MALT lymphomas.
Conclusion
MALT lymphomas constitute the majority of orbital and
periorbital non-Hodgkin’s lymphomas. Clinical signs and
symptoms are unspecific, but a slowly growing painless
orbital or periorbital swelling was masking a lymphoma
in the majority of our patients. From this perspective,
the cranio-maxillofacial surgeon plays an integral part in
the multidisciplinary management of patients with or-
bital lymphomas. Early surgical biopsy together with ad-
equate imaging studies is essential for early and
adequate diagnosis of orbital lymphoma. As demon-
strated in our patients, radiotherapy is an effective treat-
ment option in patients with stage IEA disease resulting
in excellent local tumor control and survival. The role of
systemic chemotherapy in MALT lymphoma is still not
well defined.
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